No Data
Zhejiang CONBA Pharmaceutical Gets China Nod for Hepatitis B Treatment
Zhejiang Conba Pharmaceutical's (600572.SH) wholly-owned subsidiary Entecavir tablets has obtained a pharmaceutical registration certificate.
On August 7th, Gelonhui announced that its wholly-owned subsidiary, Zhejiang Jinhua Conba Bio-Pharmaceutical Co., Ltd. (referred to as Jinhua Conba), received the drug registration certificate for entecavir tablets with specifications of 0.5mg and 1mg issued and approved by the National Medical Products Administration. Entecavir tablet is a nucleoside analogue of guanine, which has an inhibitory effect on the polymerase of hepatitis B virus (HBV). It is suitable for the treatment of chronic adult hepatitis B with active viral replication, sustained elevation of serum alanine aminotransferase (ALT), or active lesions shown in liver histology.
Are Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Zhejiang Conba Pharmaceutical (600572.SH) shareholder has accumulated a 2.27% shareholding in the company.
Zhejiang Conba Pharmaceutical (600572.SH) announced that as of July 30, 2024, its controlling shareholder Zhejiang Medicine Group had accumulated...
Zhejiang Conba Pharmaceutical (600572.SH): plans to acquire a minority stake in its subsidiary Traditional Chinese Medicine.
On July 22, Gelun Hui reported that Zhejiang Conba Pharmaceutical (600572.SH) announced that, in order to further streamline the equity relationship of the company's non-prescription drug business unit, promote the integrated operation and resource integration of the non-prescription drug business unit, after review and approval by the company's board of directors, it agreed to acquire Jiyi (Deqing) Enterprise Management Partnership Enterprise (Limited Partnership) (referred to as Jiyi Partnership Enterprise) and Xu Jianhong's stake-holding company-controlled subsidiary Zhejiang Conba Chinese Medicine Co., Ltd. (referred to as Conba Chinese Medicine, the target company) with a total equity of 20.161% (referred to as minority equity). According to the asset evaluation result, the total transaction amount was determined through negotiations as 3.
Zhejiang Conba Pharmaceutical (600572.SH): Completed repurchase, has actually repurchased 2.47% of the company's shares.
On July 22, Gelunhui reported that Zhejiang Conba Pharmaceutical (600572.SH) announced that as of July 21, 2024, the company had completed the buyback and actually repurchased 63.579048 million shares of the company's stock, accounting for 2.47% of the company's total share capital of 2570.037319 million shares. The highest buyback price was 5.00 yuan/share, the lowest buyback price was 4.08 yuan/share, and the average buyback price was 4.72 yuan/share. The total amount of funds used was 299.9241 million yuan (excluding transaction fees such as stamp duty and trading commissions), and the buyback amount was within the planned buyback range.
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Shares Lagging The Market But So Is The BusinessNo Data
